主讲人
发表于 2025-3-23 11:45:43
http://reply.papertrans.cn/63/6225/622456/622456_11.png
CHAFE
发表于 2025-3-23 16:16:11
Approaches Targeting Androgen Synthesis (CYP 17 Inhibitors)econdary hormonal manipulation in castration resistant prostate cancer. Abiraterone acetate, the first in class of these therapies to receive multi-national regulatory approval and widespread clinical use, has become a new standard of care in patients with prior docetaxel chemotherapy as well as for
Boycott
发表于 2025-3-23 19:20:13
http://reply.papertrans.cn/63/6225/622456/622456_13.png
词汇表
发表于 2025-3-23 22:22:57
http://reply.papertrans.cn/63/6225/622456/622456_14.png
Arroyo
发表于 2025-3-24 02:58:03
Bone-Targeted Therapy: Rationale and Current Statusc fracture, the requirement of surgery or radiation to bone or spinal cord compression. SREs are associated with pain, loss of function, and decreased survival. Therefore, preventing SREs is a key consideration in the treatment of mCRPC. Osteoclast-targeted agents such as the bisphosphonate zoledron
jumble
发表于 2025-3-24 08:49:21
http://reply.papertrans.cn/63/6225/622456/622456_16.png
种子
发表于 2025-3-24 11:32:55
http://reply.papertrans.cn/63/6225/622456/622456_17.png
彻底明白
发表于 2025-3-24 16:25:02
Phase I–II Targeted Treatmentsd further potential therapeutic targets. Optimizing the clinical development of novel anticancer drugs therefore remains an urgent priority in CRPC. In this chapter we will review issues specific to conducting Phase I and II clinical trials of targeted therapies for men with CRPC, including: trial d
没收
发表于 2025-3-24 19:17:00
Defining Clinical Endpoints in Castration-Resistant Prostate Cancerhe ability to improve overall survival (OS). The introduction of these novel compounds in our treatment armamentarium will likely challenge future drug development and registration strategies for new agents undergoing clinical testing in this patient population. The utility of endpoints including pr
fodlder
发表于 2025-3-25 02:56:21
Angiogenesis Inhibition in Castration-Resistant Prostate Cancerin oncology. The pathophysiology of neovascularization has been well described in prostate cancer as well as other tumors. Identification and characterization of numerous biochemical pathways contributing to angiogenesis in cancer have allowed for the development of anti-angiogenic drugs. The applic